Clinical characteristics of patients receiving MNV/r while on chronic warfarin therapy
| . | N = 29 . |
|---|---|
| Age, median (IQR), y | 70 (51-90) |
| Sex, n (%) | |
| Female | 12 (41.4) |
| Male | 17 (58.6) |
| Indication for warfarin, n (%) | |
| Atrial fibrillation | 14 (48.3) |
| Venous thromboembolism | 7 (24.1) |
| Mechanical heart valve | 6 (20.6) |
| Other∗ | 2 (6.9) |
| Target INR, n (%) | |
| 1.5-2.5 | 1 (3.4) |
| 2.0-3.0 | 26 (89.6) |
| 2.5-3.5 | 2 (6.9) |
| Time in therapeutic range for prior 12 months, median (IQR) | 74 (36-100) |
| INR before start of NMV/r, median (IQR) | 2.4 (1.1-3.7) |
| INR after start of NMV/r, median (IQR) | 1.95 (1.5-2.3) |
| . | N = 29 . |
|---|---|
| Age, median (IQR), y | 70 (51-90) |
| Sex, n (%) | |
| Female | 12 (41.4) |
| Male | 17 (58.6) |
| Indication for warfarin, n (%) | |
| Atrial fibrillation | 14 (48.3) |
| Venous thromboembolism | 7 (24.1) |
| Mechanical heart valve | 6 (20.6) |
| Other∗ | 2 (6.9) |
| Target INR, n (%) | |
| 1.5-2.5 | 1 (3.4) |
| 2.0-3.0 | 26 (89.6) |
| 2.5-3.5 | 2 (6.9) |
| Time in therapeutic range for prior 12 months, median (IQR) | 74 (36-100) |
| INR before start of NMV/r, median (IQR) | 2.4 (1.1-3.7) |
| INR after start of NMV/r, median (IQR) | 1.95 (1.5-2.3) |
Includes a patient each with antiphospholipid antibody syndrome and intracardiac thrombosis.